Literature DB >> 15205341

Molecular causes of the aberrant choline phospholipid metabolism in breast cancer.

Kristine Glunde1, Chunfa Jie, Zaver M Bhujwalla.   

Abstract

Proton magnetic resonance spectroscopy ((1)H MRS) consistently detects significant differences in choline phospholipid metabolites of malignant versus benign breast lesions. It is critically important to understand the molecular causes underlying these metabolic differences, because this may identify novel targets for attack in cancer cells. In this study, differences in choline membrane metabolism were characterized in breast cancer cells and normal human mammary epithelial cells (HMECs) labeled with [1,2-(13)C]choline, using (1)H and (13)C magnetic resonance spectroscopy. Metabolic fluxes between membrane and water-soluble pool of choline-containing metabolites were assessed by exposing cells to [1,2-(13)C]choline for long and short periods of time to distinguish between catabolic and anabolic pathways in choline metabolism. Gene expression analysis using microarrays was performed to understand the molecular mechanisms underlying these changes. Breast cancer cells exhibited increased phosphocholine (PC; P < 0.001), total choline-containing metabolites (P < 0.01), and significantly decreased glycerophosphocholine (P < 0.05) compared with normal HMECs. Decreased (13)C-enrichment was detected in choline (P < 0.001) and phosphocholine (P < 0.05, P < 0.001) of breast cancer cells compared with HMECs, indicating a higher metabolic flux from membrane phosphatidylcholine to choline and phosphocholine in breast cancer cells. Choline kinase and phospholipase C were significantly overexpressed, and lysophospholipase 1, phospholipase A2, and phospholipase D were significantly underexpressed, in breast cancer cells compared with HMECs. The magnetic resonance spectroscopy data indicated that elevated phosphocholine in breast cancer cells was primarily attributable to increased choline kinase activity and increased catabolism mediated by increased phospholipase C activity. These observations were consistent with the overexpression of choline kinase and phospholipase C detected in the microarray analyses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15205341     DOI: 10.1158/0008-5472.CAN-03-3829

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  139 in total

1.  In vivo proton MR spectroscopy of pancreatic neuroendocrine tumors in a multiple endocrine neoplasia type 1 conditional knockout mouse model.

Authors:  Min-Hui Cui; Craig A Branch; Sean M Cahill; Thomas J Quinn; Asha Adem; Steven K Libutti; Ziqiang Yuan
Journal:  Magn Reson Med       Date:  2014-11-13       Impact factor: 4.668

Review 2.  Development of radiotracers for oncology--the interface with pharmacology.

Authors:  Rohini Sharma; Eric Aboagye
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

3.  Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer.

Authors:  Maria D Cao; Mailin Döpkens; Balaji Krishnamachary; Farhad Vesuna; Mayur M Gadiya; Per E Lønning; Zaver M Bhujwalla; Ingrid S Gribbestad; Kristine Glunde
Journal:  NMR Biomed       Date:  2012-01-26       Impact factor: 4.044

4.  Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells.

Authors:  Egidio Iorio; Alessandro Ricci; Marina Bagnoli; Maria Elena Pisanu; Giancarlo Castellano; Massimo Di Vito; Elisa Venturini; Kristine Glunde; Zaver M Bhujwalla; Delia Mezzanzanica; Silvana Canevari; Franca Podo
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

5.  Multivariate statistical identification of human bladder carcinomas using ambient ionization imaging mass spectrometry.

Authors:  Allison L Dill; Livia S Eberlin; Anthony B Costa; Cheng Zheng; Demian R Ifa; Liang Cheng; Timothy A Masterson; Michael O Koch; Olga Vitek; R Graham Cooks
Journal:  Chemistry       Date:  2011-01-31       Impact factor: 5.236

6.  MR Spectroscopy in the diagnosis and treatment of breast cancer.

Authors:  Michael T Nelson; Lenore I Everson; Michael Garwood; Tim Emory; Patrick J Bolan
Journal:  Semin Breast Dis       Date:  2008-06-01

Review 7.  Biochemical characterization of breast tumors by in vivo and in vitro magnetic resonance spectroscopy (MRS).

Authors:  Uma Sharma; Naranamangalam R Jagannathan
Journal:  Biophys Rev       Date:  2009-01-17

8.  Nuclear magnetic resonance detects phosphoinositide 3-kinase/Akt-independent traits common to pluripotent murine embryonic stem cells and their malignant counterparts.

Authors:  Hanna M Romanska; Stefano Tiziani; Rachael C Howe; Ulrich L Günther; Zulfiqar Gulzar; El-Nasir Lalani
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

Review 9.  Clinical applications of metabolomics in oncology: a review.

Authors:  Jennifer L Spratlin; Natalie J Serkova; S Gail Eckhardt
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

10.  [18F]fluoromethyl-[1,2-2H4]-choline: a novel radiotracer for imaging choline metabolism in tumors by positron emission tomography.

Authors:  Julius Leyton; Graham Smith; Yongjun Zhao; Meg Perumal; Quang-De Nguyen; Edward Robins; Erik Arstad; Eric O Aboagye
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.